Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

#1688

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Aim(s): The objective was to examine the clinicopathological and molecular features of pNEC and to assess the response to chemotherapy and survival in a multicenter, retrospective analysis.

Materials and methods: A total of 100 patients diagnosed with pNEC were enrolled. After the histological review, 70 pNECs were grouped into WDNET-G3 and PDNEC. The clinicopathological and molecular features of WDNET-G3 and PDNEC were characterized.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,